ロード中...
Do single‐arm trials have a role in drug development plans incorporating randomised trials?
Often, single‐arm trials are used in phase II to gather the first evidence of an oncological drug's efficacy, with drug activity determined through tumour response using the RECIST criterion. Provided the null hypothesis of ‘insufficient drug activity’ is rejected, the next step could be a rand...
保存先:
| 出版年: | Pharm Stat |
|---|---|
| 主要な著者: | , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley and Sons Inc.
2015
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4855632/ https://ncbi.nlm.nih.gov/pubmed/26609689 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pst.1726 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|